Liontrust GF SF Pan-European Growth Fund

The Fund returned -17.2% over the quarter in euro terms, performing the MSCI Europe Index’s -9.0% (which is the comparator benchmark)*^†.

Prevailing conditions continue to offer considerable headwinds for our Sustainable Future investment approach, with central banks around the world still raising interest rates to curb inflation. As we have written before, for companies where the market expects growth for years to come, a large proportion of the valuation is attributed to cash flows in the future (known as long duration); conversely, for stocks with lower expectations, less value is ascribed to future growth and the bulk of the value is in near-term cash flows.

Companies with strong growth expectations, therefore, have higher sensitivity to interest rate changes than those with lower growth prospects, with the market discounting future earnings more heavily and bringing down their present valuation as a result. This shift has hit our funds hard given their growth bias and longer duration relative to the market. Figures above show this portfolio has fallen more than benchmarks but, to reiterate, the MSCI index contains many currently outperforming ‘value’ companies in oil, tobacco and defence sectors, where we have never invested.

We have recently reviewed each of our holdings to ensure that, in this new higher interest rate and inflation world, our conviction remains strong, and, in almost all cases, it does. We have therefore not altered our portfolios significantly; this may sound as if we are not managing the assets actively but it has never been our approach to trade rapidly, only when necessary.

Looking forward, we cannot say exactly when the qualities of the businesses we own will become evident in their share prices; what we can say is that we have used the same approach for more than 20 years and it has served our clients well. There have been weaker periods of performance as a consequence of value rallies – notably in 2003, 2009 and 2016 – but by sticking to our process, we have more than compensated for these over the last 21 years and are confident that backing sustainable businesses is the path to making good recent underperformance once again.

There are many businesses in the portfolio offering significantly higher upside potential after recent derating and we are as positive on opportunities as we have been for several years.

Against such a challenging short-term backdrop, a handful of our holdings were still able to post positive returns in Q2, with consumer goods giant Unilever among the strongest contributors. After a drop in the company’s shares since a September 2019 peak, news of activist investor Nelson Peltz taking a stake and joining the board was welcomed by the market. Peltz has a track record of driving change and his arrival comes as Unilever has faced criticism for its recent corporate direction, particularly a £50 billion bid for GlaxoSmithKline’s consumer drugs business earlier this year.

Reiterating its sustainable credentials, with the company held under our Leading ESG management theme, Unilever announced it has achieved top spot in the GlobeScan SustainAbility Leaders Survey for the twelfth consecutive year in June, highlighting businesses showing commitment to integrating sustainability.

Other solid performers included French payment company Edenred again, which we own under our Improving the resource efficiency of industrial and agricultural processes theme. Edenred’s payment solutions bring efficiency and value for money for customers and it has benefited from an environment of higher inflation where companies are having to offer higher wages to attract and retain talent. This comes on the back of record earnings and growth for 2021, with this cash generation allowing the business to strengthen its financial profile and pay out a higher dividend than before the pandemic, while also maintaining an ambitious M&A strategy.

Qiagen and Grifols, held under our Enabling innovation in healthcare and Providing affordable healthcare themes respectively, also had a strong period. Qiagen provides molecular diagnostics technologies for use in the clinical and life science sectors and shares rose as the company was able to increase its full-year 2022 net sales outlook to at least $2.12 billion. Grifols, meanwhile, announced what it called a strategic and transformational acquisition over the period, buying haematology and clinical immunology business Biotest. This deal is expected to expand its product portfolio, increase the availability of plasma therapies for patients, and drive revenue growth and margin expansion.

Finally, we would highlight positive contributions from two UK businesses that underline our long-term approach, with Trainline and Compass Group among the hardest hit in the portfolio during Covid lockdowns.

Trainline faced additional uncertainty as the UK government announced plans to create a new public sector body to oversee Britain's railways, with fears this could threaten its business model as an online platform for tickets and railcards. This ambiguity now appears to be receding and we feel Trainline is well placed to win the government’s contract to white label the train ticket solution, as well as potentially benefiting from a major growth opportunity in Europe as that market is democratised and opens up to independent providers.

Compass Group, meanwhile, continues to recover from lockdowns, recently hitting the key milestone of revenue exceeding pre-Covid levels on a run rate basis. The catering business said it has seen a notable improvement in Business & Industry and Education sectors as employees return to the office and students to in-person learning, with this allowing the company to increase FY 2022 organic revenue guidance from 20-25% to around 30% and start a share buyback programme.

We added to both companies at depressed levels in the wake of Covid lockdowns and the market is now recognising their improving prospects with higher share prices.

Among weaker performers, as has been the case since the value rotation began, are several technology-focused businesses that continue to suffer from higher discount rates, including names such as Zur Rose, Trustpilot, Spotify and Nagarro. We have outlined our ongoing conviction in these and other indiscriminately sold-down businesses in previous commentaries and would make the additional comment that they have all executed well on growth plans.

Trustpilot, for example, is becoming the world’s leading review platform, allowing an independent and objective space for customers and merchants to interact online. As the economy continues to digitise, we believe Trustpilot’s dominant position in this fast-growing market will result in strong cashflow generation over the long term with millions of reviewers and merchants on this two-sided platform. The shares have dropped precipitously since IPO in March 2021, yet the results continue to positively surprise us. While the market might want to see profitability sooner than the company is targeting, currently guiding to EBITDA profitability in FY24, Trustpilot is delivering exactly what it set out at IPO.

Digital engineering business Nagarro, meanwhile, recently updated its profit guidance yet again and continues to see rising demand from clients looking to digitise in order to drive efficiency, and yet despite firing on all cylinders, the share price has been falling.

Our experience over the years has shown that indiscriminate sell-offs provide opportunities to add to our highest-conviction companies at more attractive valuations and we continued increasing exposure to most of these beaten-down names over the quarter. Such derating also allows us to start positions in stocks we have long admired but, prior to now, were fairly valued by the market and we added Sartorius Stedim in Q2, which has been on our watchlist for some time.

This is a leading German bioprocessing equipment and consumables manufacturer, with its products used by the pharmaceutical industry in the development and manufacture of ground-breaking treatments (biologics) including gene and cell therapy. Sartorius’s equipment enables its customers to develop this next generation of healthcare in a cost-efficient, operationally flexible and environmentally friendly manner and is therefore another strong fit for our Enabling innovation in healthcare theme.

The biologics market is growing around 8-10% per annum, as these outgrow small-molecule drugs as more effective and targeted treatments. As for bioprocessing, this is expected to grow more like 10-12% as products in clinical trials move through to commercial manufacture and, with a shift from reusable to single-use technology, companies focused on the latter have an additional tailwind.

Over the quarter, we made the call to sell our position in German braking system manufacturer Knorr Bremse, which we added back in 2019. While we like the company from a product perspective, with strong exposure to transport safety (in trains and trucks), and returns have been high, we have been concerned about recent management churn from a governance standpoint.

Most recent CEO Jan Mrosik left the company at the end of April and, to give some history, was the third chief executive since Knorr Bremse listed in 2018. We have downgraded our Matrix Rating to A4 as a result, as we have little confidence the business will be able to execute a credible strategy, not least on M&A given its aborted attempt to buy Hella – even if they insisted this was a communication issue.

While our original thesis was based around safety and braking systems in trains, fundamentals have also weakened in China, the company’s biggest market in this area. Given the latest CEO departure, we believe this puts Knorr Bremse’s medium-term group sales and EBIT margin targets in doubt; if it can keep to original aspirations, the company looks cheap, but having lost confidence in the senior management team, we choose to watch this from the sidelines rather than our clients being invested. 

Discrete years' performance*, to previous quarter-end:
Past performance does not predict future returns.

 
*Source: FE Analytics, as at 30.06.22, primary share class, in euro terms, total return, net of fees and income reinvested.

Key Features of the Liontrust GF SF Pan-European Growth Fund

KEY RISKS

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

Some of the Funds managed by the Sustainable Future team involve foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. Investment in Funds managed by the Sustainable Future team involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The value of fixed income securities will fall if the issuer is unable to repay its debt or has its credit rating reduced. Generally, the higher the perceived credit risk of the issuer, the higher the rate of interest. Some Funds may invest in derivatives. The use of derivatives may create leverage or gearing. A relatively small movement in the value of a derivative's underlying investment may have a larger impact, positive or negative, on the value of a fund than if the underlying investment was held instead.

DISCLAIMER

This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust.